The microRNA signature of patients with sunitinib failure: regulation of UHRF1 pathways by microRNA-101 in renal cell carcinoma
Metrics: PDF 972 views | HTML 1512 views | ?
Yusuke Goto1,2, Akira Kurozumi1,2, Nijiro Nohata3, Satoko Kojima4, Ryosuke Matsushita5, Hirofumi Yoshino5, Kazuto Yamazaki6, Yasuo Ishida6, Tomohiko Ichikawa2, Yukio Naya4, Naohiko Seki1
1Department of Functional Genomics, Chiba University Graduate School of Medicine, Chiba, Japan
2Department of Urology, Chiba University Graduate School of Medicine, Chiba, Japan
3Moores Cancer Center, University of California, San Diego, La Jolla, CA, United States of America
4Department of Urology, Teikyo University Chiba Medical Center, Chiba, Japan
5Department of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan
6Department of Pathology, Teikyo University Chiba Medical Center, Chiba, Japan
Naohiko Seki, email: email@example.com
Keywords: microRNA, renal cell carcinoma, sunitinib, miR-101, UHRF1
Received: June 20, 2016 Accepted: July 19, 2016 Published: July 28, 2016
Molecular targeted therapy is a standard treatment for patients with advanced renal cell carcinoma (RCC). Sunitinib is one of the most common molecular-targeted drugs for metastatic RCC. Molecular mechanisms of sunitinib resistance in RCC cells is still ambiguous. The microRNA (miRNA) expression signature of patients with sunitinib failure in RCC was constructed using a polymerase chain reaction (PCR)-based array. Several miRNAs that were aberrantly expressed in RCC tissues from patients treated with sunitinib were identified in this analysis. MicroRNA-101 (miR- 101) was markedly suppressed in sunitinib treated RCC tissues. Restoration of miR-101 significantly inhibited cell migration and invasion in Caki-1 and 786-O cells. Ubiquitin-like with PHD and ring finger domains 1 (UHRF1) was directly suppressed by miR-101 in RCC cells, and overexpression of UHRF1 was confirmed in sunitinib-treated RCC tissues. The pathways of nucleotide excision repair and mismatch repair were significantly suppressed by knockdown of UHRF1. Our findings showed that antitumor miR-101- mediated UHRF1 pathways may be suppressed by sunitinib treatment.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.